貝達藥業(300558.SZ):擬向實控人控制的公司出售貝達醫藥科技全部股權
格隆匯6月14日丨貝達藥業(300558.SZ)公佈,浙江貝達醫藥科技有限公司(“標的公司”或“貝達醫藥科技”)為公司全資子公司,主要承擔貝達夢工場海創園生物醫藥孵化基地的建設,目前海創園基地已建設完成。
為實現建設資金的快速回籠,加大支持創新藥開發業務,加速提升核心競爭力,公司擬向寧波凱銘創新科技有限公司(“凱銘創新”)出售持有的標的公司全部股權。
以2020年3月31日為評估基準日,貝達藥業持有的標的公司全部權益價值為25146.35萬元,評估增值27030.76 萬元,增值率1434.44%。參考前述評估值,雙方協商一致同意此次交易對價約2.51億元。
凱銘創新系公司實際控制人丁列明控制的公司,丁列明持有其100%股權並擔任法定代表人。根據《深圳證券交易所創業板股票上市規則》的規定,凱銘創新屬於貝達藥業關聯方,此次交易構成關聯交易但不構成《上市公司重大資產重組管理辦法》規定的重大資產重組。根據《深圳證券交易所創業板股票上市規則》、《公司章程》和公司《關聯交易決策制度》的相關規定,該等交易已經公司第三屆第七次董事會以8票贊成審議通過,關聯董事丁列明迴避表決,獨立董事發表了事前認可意見和明確同意的獨立意見。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.